Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“KRAS G12D is no longer ‘undruggable.’ But are we really there yet?
Setidegrasib (ASP3082) – a first-in-class KRAS G12D degrader – shows promising signals in a phase 1 study:
NSCLC
- ORR: 36%
- mPFS: 8.3 months
Pancreatic cancer
- ORR: 24%
- mPFS: 3.0 months
Same biology, very different outcomes.
Pancreas still remains the real challenge.
This is not just inhibition – this is targeted protein degradation.
But the real questions begin now:
- Will degraders provide deeper and more durable responses than inhibitors?
- Could resistance mechanisms be different – or delayed – with protein degradation?
- Which combinations will unlock real benefit?
- Especially: Will IO-based combinations finally work in KRAS G12D tumors?
The era of KRAS targeting is evolving – but the real battle is just starting. What are your thoughts?”
Title: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Authors: Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Jonathan W. Goldman
Other articles about NSCLC on OncoDaily.
